Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

AMALIA Massively Scalable Platform for Dual-Mode Discovery of Anti-Amyloid Drugs

Coordinator
Fundacio Institut De Bioenginyeria De Catalunya, Spain
Runs
1 May 2026 to 31 October 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101289202

What the project is doing

In the project's own words, from its summary on CORDIS.

Amyloids are protein aggregates that underlie Alzheimer’s, Parkinson’s, and other devastating diseases, yet effective therapies remain elusive. A key bottleneck is our limited ability to study and target the earliest steps of amyloid formation, which are difficult to probe with existing approaches and poorly suited for large-scale discovery. AMALIA addresses this gap by establishing a dual, massively scalable platform for anti-amyloid drug discovery, combining complementary assays that target aggregation through distinct mechanisms.

This project will validate AMALIA as a scalable and versatile platform for anti-amyloid drug discovery and downstream translation. Enabling parallel, cost-effective discovery across multiple amyloid targets, AMALIA has the potential to fundamentally change how anti-amyloid therapeutics are developed.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI